A comprehensive review on rational and effective treatment strategies against an invisible enemy; SARS Cov-2 infection by Aktas, Gulali
  
Exp Biomed Res 2020; 3(4): 293-311                                           DOI: 10.30714/j-ebr.2020463629                                               
                                                                                                                            





A comprehensive review on rational and effective treatment strategies against an 
invisible enemy; SARS Cov-2 infection  
 
Gulali Aktas 
Department of Internal Medicine, Bolu Abant Izzet Baysal University, School of Medicine, Bolu, Turkey 
 
A B ST R AC T  
 
The year 2020 is began with the declaration of a pandemic of novel coronavirus, which first occurred 
by the end of 2019 in Wuhan region of China. The novel virus infection is so called as Covid-19 or 
SARS Cov-2. The infection rapidly spread all over the world and changed the lives of millions. In 
this extended review, we aimed to discuss current and possible treatment strategies against SARS 
Cov-2 infection. Treatment options mentioned here include but not limited to 
chloroquine/hydroxychloroquine, favipiravir, remdesivir, lopinavir/ritonavir, umifenovir, steroids, 
cepharanthine, convalescent plasma, anticoagulants and monoclonal antibodies. In conclusion, 
mainstay of the SARS Cov-2 treatment is general measures such as patient isolation and supportive 
care. However, encouraging developments are being achieved in terms of discovery of an effective 
treatment and production of a potent vaccine. 
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Introduction 
By the end of 2019, a new pandemic of 
coronavirus (Covid-19 or namely, SARS Cov-
2) arose from China and rapidly spread to the 
rest of the world. It is not only an important 
infectious disease but also a concern of public 
health emergency [1]. Angiotensin-converting 
enzyme 2 (ACE2) receptors play important role 
in the infection since surface spike proteins of 
the virus bind to these receptors and enter the 
human cells [2]. Type II alveolar cells in the 
lungs express ACE2 receptors, therefore, 
devastating effects of the infection mainly 
occur in the lungs [3]. Heart, kidneys, vascular 
endothelium and intestinal epithelium also 
express ACE2 which could be the underlying 
mechanism of multiorgan dysfunction and 
micro-thrombi formation that caused by SARS 
Cov-2 [4,5]. Although the SARS Cov-2 
infection could be asymptomatic, about 15% of 
the patients complicate with the severe course 
of the disease [6]. The infection could begin 
with flu-like symptoms. Indeed, nearly 2 or 3 of 
every 4 subjects that have positive RT-PCR 
throat swab results remain without symptoms 
and only in 10% of the symptomatic patients 
develop dyspnea, interstitial pneumonia, ARDS 
and/or multiorgan dysfunction [7]. Fever, 
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headache, myalgia, fatigue, rhinorrhea, cough, 
mild dyspnea, sore throat and conjunctivitis are 
common symptoms of the disease [8,9], which 
all seen in other respiratory conditions as well. 
Rare presentations of the infection include 
diarrhea, nausea and vomiting [10]. 
Determining the mortality rate of SARS Cov-2 
infection is difficult since it might be an earlier 
period of the pandemic, however, Jiang et al 
reported the mortality rate of the disease was 
3% [11]. Although this rate is lower than 
previous coronavirus infections; severe acute 
respiratory syndrome (SARS) and middle east 
respiratory syndrome (MERS), which have 
mortality rate of 10% and 35%, respectively, 
elderly population and subjects with chronic 
diseases (i.e. diabetes mellitus, hypertension, 
heart failure, coronary heart disease) tend to 
have more serious clinical course and increased 
risk of death. As of 29th of September in 2020, 
33,249,563 people infected with Covid-19 and 
1,000,040 of them died in the whole world [12]. 
More than half of the cases (16,434,186) and 
deaths (551,313) were reported from North and 
South America [12]. Unluckily, to date, there is 
no proven and effective treatment against 
SARS Cov-2 infection [13]. However, several 
drugs and attempts to develop a vaccine are on 
the way. 
The purpose of this review is evaluating the 
current experimental and clinical treatment 
options of SARS Cov-2 infection, as well as 
focusing the attempts on developing an 
effective vaccine for the disease. 
 
Current treatment option of SARS Cov-2 
 
Oxygen supplementation 
This is an important step in the management of 
SARS Cov-2 after obtaining protective 
measures such as isolation of the patients. A 
number of subjects with SARS Cov-2 may 
develop hypoxemia during the course of the 
infection.  Supplemental oxygen is indicated if 
the oxygen saturation drop below 93% or in 
cases with evident respiratory distress [10]. 
Face mask, nasal cannula or non-invasive 
ventilation are the routes of oxygen therapy 
[14]. Prone positioning may be useful in oxygen 
supplementation [15]. Indeed, most of the 
patients in critical care may respond well to 
prone positioning [14,16]. Endotracheal 
intubation is evitable when the oxygen 
saturation is not reached to target levels.  
 
Chloroquine/hydroxychloroquine 
Chloroquine and Hydroxychloroquine are 
antimalarial drugs which are also used in 
rheumatologic diseases. They have 
immunomodulatory effect and were used 
against SARS and MERS since they reduced 
viral replication [17,18]. Hydroxychloroquine 
is useful in the treatment of autoimmune 
disorders (i.e. rheumatoid arthritis and 
Sjögren’s syndrome) since it decrease the 
serum levels of inflammatory cytokines [19]. 
These effects of the drug might be promising in 
the severe form of SARS Cov-2, which is 
associated with cytokine storm.  
The first human Covid-19 study about the 
efficacy of chloroquine showed that duration of 
the symptoms and severity of the pneumonia 
was reduced in subjects treated with 
chloroquine [20]. In a following study, authors 
compared the nasopharyngeal viral clearance 
on 6th day of the subjects received 
hydroxychloroquine or hydroxychloroquine 
plus azithromycin to the controls and reported 
higher clearance rate in subjects received 
hydroxychloroquine plus azithromycin (100%) 
than the patients received hydroxychloroquine 
alone (57%) and the controls (12.5%) [21]. 
However, the efficacy of these drugs against 
SARS Cov-2 infection is controversial. Wang 
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et al. and Colson et al reported that chloroquine 
was effectively reduced viral replication in an 
in vitro study [18,22]. Moreover, antibiotic 
treatment to prevent bacterial infection is lack 
of evidence [10].  
These drugs’ antiviral effects are driven by the 
immunomodulatory effects, by increased 
cytoplasmic pH and by glycosylation of cellular 
receptors of the virus [22]. Glycosylation of 
cellular receptors may prevent viral binding to 
ACE2 receptors [23,24]. Both chloroquine and 
hydroxychloroquine act similarly and prevent 
the membrane fusion by changing the pH of 
acidic intracellular organelles (endosome, 
lysosome) [19]. Therefore, authors believe that 
these agents could be effective in treatment of 
SARS and SARS Cov-2 infections [18,25].  
Sialic acid, which is a monosaccharide required 
for ligand recognition and is a part of receptors 
that used as ligand by coronaviruses and 
orthomyxoviruses [19]. Chloroquine prevents 
the synthesis of sialic acid by inhibiting the 
enzyme quinone reductase-2 [19].  This 
inhibition could be responsible of the broad 
antiviral effects of chloroquine [19]. Moreover, 
chloroquine interferes with the virion budding 
of SARS Cov-2 via inhibition of MAP-kinase 
molecular crosstalk [18,22].  
In vitro studies showed that 
hydroxychloroquine is superior to chloroquine 
in inhibition of SARS Cov-2 infection [26,27].  
Beside effectiveness, chloroquine also provides 
an affordable treatment for the infection, since 
it is inexpensive. A Chinese consensus report 
that published in February 2020, declared that 
chloroquine 500 mg twice daily for ten days 
was recommended for SARS Cov-2 pneumonia 
[28]. Netherlands control of disease control also 
recommended treatment with chloroquine, but 
only for those that necessitate hospitalization, 
oxygen supplementation or intensive care 
support [29]. Moreover, an Italian guide by 
Italian Society of Infectious and Tropical 
disease also suggest treatment with chloroquine 
or hydroxychloroquine for 10 days for patients 
with SARS Cov-2 infection [30]. In addition, a 
Korean task force recommended chloroquine or 
hydroxychloroquine in treatment of moderate 
and severe SARS Cov-2 cases [31]. Despite 
both 500 mg twice daily chloroquine and 200 
mg twice daily hydroxychloroquine are 
suggested as effective treatments for SARS 
Cov-2 [1,32], optimal therapy requires a 
loading dose before maintaining dose [33].  
Side effects of chloroquine include QT interval 
prolongation in electrocardiography, 
hematological disorders (anemia, leukopenia, 
and thrombocytopenia), elevation in liver 
enzymes, serum electrolyte disturbances, 
elevation in renal function tests and visual 
deterioration. QT prolongation is the most 
important side effect and this side effect may be 
potentiated by concomitant use of other drugs 
that increase QT interval, such as, macrolide 
antibiotics, antiarrhythmic agents, 
antidepressants, antipsychotics, ondansetron 
and quinolones. Therefore, close 
monitorization of the patients regarding 
hemogram and ECG is advised.  
 
Favipiravir 
Favipiravir is a purine nucleic acid analog that 
target RNA viruses by potently and 
competitively inhibiting the RNA-dependent 
RNA polymerase [34].  
Favipiravir is very effective against infections 
with influenza A, B and C viruses that resistant 
to oseltamivir [35]. Novel studies reported its 
efficacy in treatment of SARS Cov-2 infection 
[36]. In addition, in vitro studies suggested its 
efficacy against SARS Cov-2 [22,37]. In a 
study from China, authors reported that 
duration of viral clearance of SARS Cov-2 was 
reduced in patients received favipiravir 
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compared to those subjects received 
lopinavir/ritonavir [38]. Moreover, in the same 
study, radiological improvement rate on day 14 
was higher and side effect rate was lower in 
favipiravir group compared to the patients 
received lopinavir/ritonavir treatment [38]. 
Therefore, it has been recommended in the 
management of this infection in China [39] and 
in Turkey [40]. Despite there are currently no 
randomized controlled clinical trial with large 
cohort about the efficacy of favipiravir in the 
treatment of SARS Cov-2, studies are on the 
way about this topic [39].  
Starting dose of favipiravir is 1600 mg two 
times on day 1, 600 mg two times a day on 2nd 
to 5th days and 600 mg once a day on 6th day of 
the treatment [39]. Adverse effects of 
favipiravir include increase in serum uric acid 
levels, elevation in hepatic enzymes and 
gastrointestinal discomfort [38,41,42].  
 
Remdesivir  
Remdesivir is a nucleotide analogue that 
promote early termination of the viral RNA 
transcription by incorporation into genetic 
material of the virus [10]. Apart from other 
antiviral agents classified as nucleotide 
analogues, it has broad antiviral spectrum 
including Pneumoviridae Filoviridae, 
Paramyxoviridae, and Orthocoronavirinae (i.e. 
coronaviruses that cause SARS and MERS) 
families [43,44].  In an animal study, 
Remdesivir improved organ functions and 
decreased viral load in mice with MERS 
infection [45]. Moreover, it has evident 
antiviral effects against SARS and MERS 
infections [46]. Good responses achieved with 
Remdesivir in the treatment of some patients 
with SARS Cov-2 in China, where the outbreak 
of Covid-19 first started [47]. In a case report 
from United States, it was reported that 
Remdesivir was effective in treatment of a 
patients with SARS Cov-2 pneumonia [48]. In 
a recent study, Remdesivir was suggested to be 
superior to placebo in achieving shorter 
recovery duration [49].  Furthermore, clinical 
improvement was noted in 65% of the subjects 
with severe SARS Cov-2 infection whom 
received remdesivir treatment [50]. However, a 
Chinese study reported that Remdesivir was not 
superior to placebo in terms of duration 
between drug initiation and clinical 
improvement [51].  
Serious adverse reactions, including rectal 
hemorrhage, liver toxicity, and nausea and 
vomiting, have been reported relate to 
remdesivir [39]. Although these adverse events 
upraise questions about Remdesivir in 
treatment of SARS Cov-2, it has great in vitro 
efficacy against the virus [43,48]. An initial 200 
mg/day of Remdesivir which followed 100 mg 
daily on 2nd day and after is advised in treatment 
of SARS Cov-2 infection [39].    
 
Lopinavir/ritonavir 
Protease inhibitors are drugs that developed for 
the treatment of human immunodeficiency 
virus (HIV) infection. New generation protease 
inhibitor, the combination of lopinavir and 
ritonavir, also shows its effect through 
inhibition of viral protease [10]. Papain-like 
protease and 3C-like protease in coronaviruses 
are target enzymes for protease inhibitors [52]. 
Lopinavir/ritonavir was suggested to be useful 
in SARS infection [53]. Several studies in 
literature suggested that this combination 
reduced the viral load in SARS Cov-2 infected 
subjects [54,55]. However, the effect of 
lopinavir/ritonavir treatment against SARS 
Cov-2 is controversial. In a novel study, 
remdesivir was suggested to be superior to 
lopinavir/ritonavir and interferon-beta 
combination in terms of reducing viral load and 
the improvement of pneumonia in subjects with 
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MERS [45]. On the other hand, there are studies 
in literature that reported no benefit of 
lopinavir/ritonavir combination greater than 
standard medical care in SARS Cov-2 infection 
[56].  
Authors speculate that serum level of 
lopinavir/ritonavir could be much lower than 
the required serum concentration to inhibit 
SARS Cov-2 replication [57]. Advised dose of 
the combination is 400mg/100mg twice a day. 
Sleeping difficulty, nausea, vomiting and 




Umifenovir is an antiviral agent that has broad 
antiviral spectrum. The drug prevents viral 
entry by blockage of the fusion between the 
virus and the cell membrane.  It blocks viral 
fusion with the target membrane, thus 
providing viral entry into target cells. 
Umifenovir is an indole derivate and its 
antiviral spectrum covers influenza viruses 
[58]. Therefore, it is approved in both treatment 
of and prophylaxis for influenza infections [59]. 
Authors retrospectively analyzed subjects with 
SARS Cov-2 infection according to hypoxic 
(mean age 70 years) and non-hypoxic (mean 
age 37 years) patients and reported that 58.2% 
of the non-hypoxic and only 33% of hypoxic 
subjects were treated umifenovir [60]. 
Moreover, it was concluded in the same study 
that 33% of subjects received umifenovir were 
discharged while 19% of the subjects that not 
received umifenovir discharged from the 
hospital, in other way to say, despite the 
mortality rate of the study population was 7.5%, 
none of the subjects received umifenovir were 
deceased [60]. It shall be speculated that 
umifenovir could increase the discharge rate 
and decrease the mortality rate in SARS Cov-2 
infection, nonetheless, age difference between 
study groups may confound the results of that 
study.  
Another study with small population compared 
umifenovir and lopinavir/ritonavir treatment to 
lopinavir/ritonavir treatment alone in patients 
with SARS Cov-2 and found that umifenovir 
and lopinavir/ritonavir combination was 
superior to lopinavir/ritonavir alone according 
to viral clearance on seventh day, improvement 
in thorax imaging, and viral clearance on 14th 
day [61].   
Reported side effects of the umifenovir include 
nausea, diarrhea and elevation in serum 
bilirubin levels [59]. Larger prospective cohort 
studies are needed to suggest for or against the 




Steroids (or namely corticosteroids) are 
immunosuppressive and anti-inflammatory 
agents with a broad clinical usage in many 
disorders. Methyl prednisolone and 
dexamethasone are two frequently prescribed 
steroids in daily practice. The use of steroids in 
patients with severe SARS, MERS and 
influenza infections reported either no 
improvement or an increase in mortality rates 
[62-64]. These nonsuggestive evidences did not 
discourage researchers to study the effects of 
steroids in the novel coronavirus pandemic. 
However, there are conflicting study results in 
literature about treatment of SARS Cov-2 with 
steroids. The role of steroids investigated in a 
small population with SARS Cov-2 whom were 
treated in intensive care unit because of 
moderate-severe ARDS, and the results of the 
study revealed that steroids did not decreased 
mortality despite hypoxia was improved in the 
subjects [65]. Similarly, addition of the steroids 
in treatment regimen reduced the fever but did 
not decreased the mortality, nor reduced the 
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resolution duration of pneumonia, nor 
decreased the length of hospitalization of SARS 
Cov-2 patients in a meta-analysis [66]. 
Moreover, low dose of steroids in short course 
to prevent cytokine storm in SARS Cov-2 
patients with disease progression did not alter 
the clinical outcome of the cases [67]. In 
contrast, Lee et al proposed early use of steroids 
in treatment of SARS Cov-2, since it could be 
difficult to reverse advanced ARDS in these 
subjects [68]. Indeed, authors reported that 
short term dexamethasone improved the 
outcome of the patients whom infected with 
novel coronavirus [69]. 
These evidences bring a question in mind 
whether steroids should be given in an earlier 
phase of the SARS Cov-2 infection instead of 
delaying to the advanced stage. The results of 
prospective studies on the way might answer 
this question successfully.  
 
Cepharanthine  
Cepharanthine is an alkaloid agent that used for 
alopecia in Japan for nearly 70 years [70]. 
Indications of the drug also include exudative 
middle-ear catarrh [70], leukopenia due to 
radiation [71], viper and other venomous snake 
bites [70], alopecia areata [72] and immune 
thrombocytopenic purpura [73]. It has also been 
effective against other coronaviruses that cause 
mild infection in human [74].  
It has also been suggested that cepharanthine 
reduces nitric oxide production in macrophages 
and prevent cell death in septic shock [75]. 
Besides nitric oxide production, it decrease 
lipid peroxidation, reduces nuclear factor-
kappa B activity, and inhibit cyclooxygenase 
pathway, thus, provide anti-inflammatory 
effects and improvement in vascular 
endothelium [76]. Cepharanthine decreases the 
serum levels inflammatory cytokines which 
include interleukin-1 beta, tumor necrosis 
factor alpha and interleukin-6, the 
inflammatory predictor that to treat SARS Cov-
2 related cytokine storm [77]. Replication of 
human immunodeficiency virus is shown to be 
inhibited by cepharanthine more than 2 decades 
ago [78]. Moreover, its use against SARS Cov-
2 and other viral infections is suggested by anti-
inflammatory, immuno-modulating and anti-
oxidative features of that phytomedicine 
[70,72]. Indeed cepharanthine was suggested to 
be an effective treatment option in SARS in 
2005 [79].  
Cepharanthine has both effects in pre and post 
entry stages of the SARS Cov-2 infection. It 
reduces viral RNA in post entry phase [80]. In 
addition viral replication is also inhibited by 
cepharanthine [81].Moreover, authors showed 
that cepharanthine has inhibitor effect on S 
glycoprotein of SARS Cov-2 virus, which is 
essential for the virus entry to human cells [82]. 
Its utility in novel pandemic is also being 
investigated since SARSCov-2 has great 
homology with SARS in terms of genomic 
features. An animal study revealed that it was 
successful in treatment of SARS Cov-2 
infection [80]. It has been reported in an 
unpublished cell culture model study that it has 
great efficacy against SARS Cov-2 [83]. 
Cepharanthine was proposed as a drug that has 
antiviral activity against SARSCov-2 [84], 
however, clinical human studies in randomized 
controlled trial form are required to 
demonstrate its efficacy in the treatment of 
SARS Cov-2 patients.  
 
Convalescent plasma 
Plasma of a patient who healed from an 
infection contains antibodies against a certain 
microorganism. Infusion of this plasma to 
another person suffering of the same infection 
is called as convalescent plasma therapy, which 
is a form of passive immunotherapy [59]. 
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Convalescent plasma therapy was used in 
previous viral infections, such as, influenza, 
SARS and Ebola [85,86]. Authors speculate 
that this treatment option might reduce 
mortality in severe viral respiratory infections, 
however, the majority of the studies suggesting 
convalescent plasma treatment were low 
quality reports without a control group [87]. 
Plasma of the patients that recovered from 
SARS Cov-2 is being used in the treatment of 
the disease. The FDA was approved its 
emergency investigational use in subjects with 
severe SARS Cov-2 infection [88]. In a case 
series, convalescent plasma found to improve 
clinical symptoms and to promote resolution of 
ARDS in SARS Cov-2 patients [86]. A case 
report including two patients from Korea 
revealed that clinical improvement and 
radiological resolution were achieved with 
plasma therapy [89]. In a study with small 
cohort, it was suggested that convalescent 
plasma was improved outcome of the patients 
with SARS Cov-2 [90]. These data suggest that 
convalescent plasma treatment may be useful in 
SARS Cov-2 infection; however, studies with 
larger population are needed to confirm its 
effectiveness in the treatment of the disease. 
Adverse reactions related to plasma therapy 
include transmission of disease, circulatory 
overload, allergic reactions and transfusion 
associated lung injury [91].   
 
Antibiotics 
During SARS Cov-2 infection, the rate of co-
infections with other microorganisms could be 
as high as 50% [39]. Influenza A virus is the 
most commonly reported virus that cause co-
infection [92]. Other causes of co-infection 
include various bacteria (including M. 
pneumonia), fungi (Candida spp.), and viral 
pathogens (other coronaviruses, rhinovirus, 
human immunodeficiency virus) [39]. At the 
early stages of the pandemic, antibacterial and 
antiviral agents against influenza were 
frequently added in the treatment regimens 
against SARS Cov-2. Moreover, patients that 
hospitalized for a week or longer may require 
effective antibacterial therapy against 
pneumococci, S. aureus, K. pneumonia, 
Pseudomonas spp. and Acinetobacter Baumanii 
[93,94].  
Azithromycin is a macrolide antibacterial agent 
which prevents concomitant bacterial 
infections during viral respiratory infections 
[95]. Moreover, it has antiviral effects in vitro, 
suggested by Madrid et al, in 2015 [96]. During 
SARS Cov-2 pandemic, it was used along with 
hydroxychloroquine in treatment of patients in 
severe condition and triggered good clinical 
outcome [21]. Azithromycin may increase liver 
enzymes and combination with 
hydroxychloroquine warrant more attention on 
prolongation of QT interval in 
electrocardiogram.   
Teicoplanin, a glycopeptide antibiotic, could be 
a promising antiviral agent as well. Cathepsins 
L and B in human cells are responsible of the 
release of viral genome into the cytoplasm by 
cleaving viral proteins [97]. Teicoplanin 
inhibits the activities of both cathepsins L and 
B, specifically [24]. Indeed, it prevents viral 
entry in Ebola, SARS and MERs infections 
[98]. These data suggest that viral infections 
that require cathepsin L to enter human cells 
may benefit from treatment with teicoplanin 
and its derivatives: dalbavancin, telavancin, and 
oritavancin [94]. Nevertheless, we think that 
randomized trials on teicoplanin treatment in 
patients with SARS Cov-2 infection are needed 
to confirm its effectiveness against the virus.   
 
Monoclonal antibodies 
Monoclonal antibodies are developed and used 
against viral infections such as influenza, SARS 
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and MERS infections [43,99,100]. 
Exacerbation of rheumatoid arthritis is being 
treated with tocilizumab, a monoclonal 
antibody that prevents binding of interleukin-6 
to its receptors [94]. It can also be effective in 
alleviating cytokine storm in patients with 
severe SARS Cov-2 infection. Therefore, its 
effectiveness in the treatment of the infection is 
being studied. In a study from China, authors 
suggested that tocilizumab was effective in 
treatment of cytokine storm during severe 
SARS Cov-2 infection [101]. Since cytokine 
storm occur in a significant amount of subjects 
with severe infection, tocilizumab could 
prevent this cytokine related damage and death 
by inhibiting the effects of interleukin-6 [102]. 
Nevertheless, evidence will accumulate about 
the role of tocilizumab in the treatment of the 
infection by growing experience on its use 
against SARS Cov-2.  
 
Anticoagulant treatment 
Besides sepsis induced coagulopathy, 
disseminated intravascular coagulation and 
venous thromboembolism (driven by prolonged 
inactivity) could occur as complications in all 
critically ill subjects, thrombotic complications 
are especially predisposed by severe SARS 
Cov-2 infection [59]. Coagulation system is 
triggered by inflammation and infection during 
SARS Cov-2 infection. Over activation of the 
coagulant factors in blood may result in 
ischemic events, thrombi formation and 
disseminated intravascular coagulation [103]. 
Indeed, the rate of thrombotic complications 
(myocardial infarction, ischemic stroke and 
arterial embolism) was reported as high as 31% 
in SARS Cov-2 subjects whom treated in 
intensive care unit [104]. A similar study from 
China reported 25% of venous thrombosis in 
cases with severe SARS Cov-2 [105]. 
Anticoagulation therapy is advised in earlier 
periods of the SARSCov-2 infection especially 
when the d-dimer levels are higher than the four 
times of upper limit of normal range [10]. Other 
markers of pro-coagulant state in SARS cov-2 
infection are increased fibrin degradation 
product levels, inflammatory predictors, and 
prolonged prothrombin time and activated 
partial thromboplastin time levels, which all 
related with the increased risk of mortality 
[106]. On the other hand, it is useful in patients 
with severe condition, too. A study by Tang et 
al suggested that heparin (mostly low molecular 
weight heparin) treatment was related with 
better prognosis and reduced mortality in 
severe SARS Cov-2 cases [107]. In contrast, 
both the durations of hospitalization and viral 
clearance of severe SARS Cov-2 patients 
received low molecular weight heparin were 
not different from the subjects that not received 
anticoagulant therapy [108]. Nevertheless, 
World Health Organization recommends 
heparin or low molecular weight heparin as a 
prophylactic treatment against venous 
thromboembolism in severe SARS Cov-2 
patients [109]. Furthermore, not only intensive 
care population but also all hospitalized SARS 
Cov-2 subjects are suggested to be prescribed 
low molecular weight heparin if it is not contra 
indicated (i.e. active bleeding, a platelet count 
lower than 25000 per microliter) [110]. 
 
Other possible treatment options 
Hepatitis C virus, several hemorrhagic fever 
viruses and respiratory syncytial virus are being 
treated with ribavirin, a nucleotide analogue. It 
has previously been used against SARS 
infection [111]. It was also proposed as an 
effective treatment option against SARS Cov-2 
in a study from Saudi Arabia [112]. Moreover, 
authors supposed that ribavirin, as a direct anti-
viral agent, could be used against SARS Cov-2 
infection [113]. Reduction in blood hemoglobin 
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is the most important side effect of ribavirin 
which may limit its use since that is harmful in 
subjects with respiratory distress [44].  
Interferon 1 beta is used in the treatment of 
MERS infection [111]. However, its effect 
against SARS was uncertain [52]. In a 
multicenter, prospective, open-labeled, 
randomized, phase 2 trial, 81 subjects enrolled 
to the treatment group that received 
combination of lopinavir 400 mg and ritonavir 
100 mg twice daily, ribavirin 400 mg twice 
daily, and three doses of 8 million IU of 
interferon 1 beta on alternate days for 14-days 
while 41 subjects received  lopinavir 400 mg 
and ritonavir 100 mg twice daily for 14 days 
and authors concluded that combination of 
lopinavir /ritonavir plus ribavirin plus 
interferon 1 beta treatment was superior to 
lopinavir/ritonavir treatment alone in 
shortening viral shedding duration, in reducing 
hospitalization time and in alleviating of the 
symptoms in mild to moderate SARS Cov-2 
cases [114].  
Melatonin has anti-inflammatory, anti-cancer 
and anti-oxidative properties. Acute lung injury 
and ARDS is prevented by melatonin [115]. 
Since it has high safety profile [116] and it 
reduces the risk of cytokine storm [117], 
growing data suggest that melatonin could be 
beneficial in treating viral infections, as well as 
SARS Cov-2 [115]. Authors found that 
increased activity of ACE2 might decrease the 
severity of the infection with respiratory 
syncytial virus [118]. On the other hand, statins 
improve endothelial functions which was 
deteriorated by viral infection, therefore, a 
combination with angiotensin receptor blocker 
and statin may enhance recovery of 
endothelium and facilitate healing of the 
patients own [119,120].  
Nitazoxanide is an antiparasitic and antiviral 
drug with broad spectrum which is converted to 
its active form; tizoxanide following oral intake 
[121]. Five day course of treatment of influenza 
with nitazoxanide 600 mg twice daily has been 
suggested to be effective in relieving symptoms 
with mild adverse events [122]. Interferons 
alpha and beta production are upregulated by 
nitazoxanide. Therefore, its activity against 
MERS and other coronaviruses were tested and 
found to be effective in vitro [123]. Promising 
results of the drug in other viral infections drive 
a proposal that nitazoxanide could be used in 
early SARSCov-2 infection in adjunctive to 
azithromycin [124]. Moreover, authors 
compare the efficacy of hydroxychloroquine 
and hydroxychloroquine plus nitazoxanide in 
patients with SARS Cov-2 and expect better 
outcome in subjects received combination 
therapy [125]. Although it is a promising 
treatment alternative in novel coronavirus 
infection, controlled trials that suggest its 
efficacy in management of the disease is still 
lacking. Studies in recent years revealed the 
antiviral effects of ivermectin. It is an anti-
microbial agent against parasitic infections, 
however, it has also broad range of antiviral 
effects. Ivermectin has been shown to inhibit 
replication of human immunodeficiency virus 
[126]. Subsequently, it was reported that 
ivermectin ameliorate the infections with 
influenza, West Nile, pseudorabies and dengue 
viruses [126,127]. In contrast, it has shown to 
be ineffective against Zika virus [128]. Caly et 
al showed in an in vitro study that ivermectin 
was potently inhibit the replication of SARS 
Cov-2 [127]. These encouraging results 
enabled the authors propose ivermectin as a 
promising candidate of SARS Cov-2 treatment 
[129]. On the other hand, randomized 
controlled trials should suggest the efficacy of 
the drug in order to recommend ivermectin 
evidently in the treatment of novel coronavirus 
pandemic. 
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It is speculated that inflammation and tissues 
damage driven by ARDS might be ameliorated 
with mesenchymal stromal cells [130]. The 
interaction between viral proteins and ACE2 
might be targeted in following research to 
develop effective treatment options [131,132].  
Isolation and amplification of cytotoxic T 
lymphocytes against SARS Cov-2 would be 
beneficial in the treatment of the disease [133]. 
T lymphocyte mediated inflammatory pathway 
would be stimulated by canakinumab or 
roflumilast [134,135]. This list may be 
prolonged as the knowledge about the SARS 
Cov-2 virus grows.  
 
Vaccines against SARSCov-2: Will full 
eradication be possible?  
Effective prophylactic strategy in disease 
control and prevention of new cases could be 
achieved with the development of a successful 
vaccine, therefore, nearly 100 vaccine research 
is ongoing worldwide [136].  
There have been 115 vaccine candidates 
worldwide as of the first half of April, 2020 
[137]. As of 25 August  2020, 31 vaccines are 
reached the level of clinical evaluation and 
phase 3 trials have been initiated for six of the 
vaccine candidates [138]. These 6 vaccine 
candidtes are being developed by University of 
Oxford/AstraZeneca, Sinovac, Wuhan Institute 
of Biological Products/Sinopharm, Beijing 
Institute of Biological Products/Sinopharm, 
Moderna/NIAID, and BioNTech/Fosun 
Pharma/Pfizer [138].  
Technologies used in the development vaccine 
against SARS Cov-2 include DNA, RNA, 
inactivated, live attenuated, non-replicating 
vector, protein subunit and replicating viral 
vector [139]. The first vaccine candidates are 
expected to be in clinical use by the end of 2020 
or in 2021. This accelerated vaccine 
development race has some risks. If a vaccine 
stimulate production of antibodies against virus 
that not neutralize its infectivity, additional 
consequences may occur via increased viral 
replication or immune complex formation 
which accumulate in the tissues and attract 
inflammatory mediators and trigger 
complement system [140].  
The first and the only confirmed vaccine by 
state health authorities against SARS Cov-2 is 
the Sputnik V vaccine of Russian researchers. 
The vaccine registered in 11th of August in 
2020 and developed by Gamaley Epidemiology 
and Microbiology National Research Center in 
Russian Federation. Despite public opinion is 
diverse and trust to the vaccine is distinct in the 
world, results of the vaccine on volunteers are 
eagerly and excitedly being awaited.  
There are currently over 169 COVID-19 
vaccine candidates under development, with 26 
of these in the human trial phase [141]. Of 
those, the phase 3 trial of the vaccine developed 
by Oxford University has been interrupted due 
to transverse myelitis, which developed in two 
of the volunteers, then the trial resumed by the 
developers [142]. 
Sputnik V SARS Cov-2 vaccine from Russia, 
Sinovac's Covid-19 vaccine from 
China, BioNTech and Pfizer's Covid-19 
vaccine from Germany are some of the other 
vaccine candidates with ongoing phase III 
trials. 
 
Novel developments in the subject 
The U.S. Food and Drug Administration (FDA) 
decided to broad the scope of emergency use 
authorization of remdesivir to include treatment 
of all adult and pediatric SARS Cov-2 patients 
in hospital era regardless of the severity of the 
disease and both in confirmed and suspected 
cases [143]. Moreover, the Solidarity trial 
which was established by WHO, discontinued 
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the hydroxychloroquine and lopinavir/ritonavir 
arms due to little or no reduction in the 
mortality of hospitalized COVID-19 patients 
[144]. In addition, as of 31 August 2020, the 
efficacy of the investigational Covid 19 
vaccine; AZD1222 has been started in 80 sites 
in United States involving 30000 volunteers 
[145].  Unusual and admirable efforts of the 
researchers continue to end the pandemic in the 
world. 
The novel study about the role of 
corticosteroids in treatment of SARS Cov-2, 
namely, RECOVERY trial showed that 
mortality rates of the hospitalized Covid-19 
patients who require supplemental oxygen or 
mechanical ventilation were significantly 




Millennium pandemic SARS Cov-2 is globally 
changed our lives and daily habits of our life. 
General measures such as patient isolation and 
supportive care are the mainstay of the SARS 
Cov-2 treatment. Luckily, encouraging 
developments are being achieved in terms of 
discovery of an effective treatment and 
production of a potent vaccine. We believe it is 
only a matter of time before we overcome the 
epidemic in cooperation. 
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